Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 601–673 of 673
Roles of HSF1 and Heat Shock Proteins in Cancer
Ohtsuka, K. (2016) · Springer eBooks · doi:10.1007/978-981-10-0719-4_4 · Cited by 1
Molecular/Targeted Therapy of Cancer
Vail, D., Thamm, D., & Liptak, J. M. (2019) · Withrow and MacEwen's Small Animal Clinical Oncology · doi:10.1016/b978-0-323-59496-7.00015-3
Inhibitors of tumor angiogenesis
Harris, A. L., & Generali, D. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50018-5 · Cited by 1
HIF‐1 Inhibitors for Cancer Therapy
Rapisarda, A., & Melillo, G. (2010) · Wiley eBooks · doi:10.1002/9780470669891.ch17 · Cited by 1
Signal Transduction Inhibitors in Renal Cell Carcinoma
Ronnen, E. A., George, S., Bukowski, R. M., & Motzer, R. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-149-3_25 · Cited by 1
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., & El‐Deiry, W. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.20.347633 · Cited by 1
Dhanani, N. N., Vocke, C. D., Bratslavsky, G., & Linehan, W. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-149-3_6 · Cited by 1
Poyya, J., & Joshi, C. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.02.595921 · Cited by 3
Targeting Hsp90 in Cancer and Neurodegenerative Disease
Neckers, L., & Ivy, P. S. (2009) · Springer eBooks · doi:10.1007/978-0-387-39717-7_15
Self-citationRegulators of angiogenesis in diabetes and tumors
Catrina, S. (2005) · Figshare
Protein factors and chemical compounds regulating hypoxic or oxidative stress responses
Oguro, A., Kobayashi, Y., & Imaoka, S. (2015) · Personalized Medicine Universe · doi:10.1016/j.pmu.2015.04.004
Signaling via the bHLH-PAS proteins AhR and HIF
Bosdotter, C. (2012) · Figshare
The Role of the Ubiquitin–Proteasome Pathway in the Regulation of the Cellular Hypoxia Response
Nakayama, K., & Ronai, Z. A. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch6b
Targeting Hypoxic Adaptations of Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities
Tang, C., & Yu, J. Q. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_14
Fujiuchi, S., Yamazaki, Y., Fujita, Y., Nishigaki, Y., TAKED, A., Yamamoto, Y., FIJIKANE, T., Shimizu, T., Osanai, S., TAKAHASHI, T., et al. (2006) · Springer eBooks · doi:10.1007/0-387-31311-7_10
Ischemia/reperfusion and colorectal liver metastases
van der Bilt, J. D. W. (2007) · Utrecht University Repository (Utrecht University)
Dhanani, N. N., Vocke, C. D., Bratslavsky, G., & Linehan, W. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_2
Hahn, O. M., & Stadler, W. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_11
of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
Han, J., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2015)
factor-2 in clear cell renal carcinoma
Kong, H., Lee, S., Beebe, K. E., Scroggins, B. T., Gupta, G. N., Jung, Y., Trepel, J. B., & Neckers, L. Μ. (2010)
Self-citationHypoxia and Angiogenesis in Glioblastomas
Acker, T., & Plate, K. H. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_11 · Cited by 1
Mardilovich, K. (2011) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/3w9g-7v51
Gene regulatory and pro-tumourigenic mechanisms of the bHLH-PAS transcription factor SIM2s.
Farrall, A. L. (2010) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Turnbull, D. W. (2008) · Scholars' Bank (University of Oregon)
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 2
Molecular/Targeted Therapy of Cancer
Sone, S., Kuramoto, T., Sato, S., Mitsuhashi, A., Kakiuchi, S., Goto, H., Tada, H., & Nishioka, Y. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2362-5.00014-1
A Novel Role for Tid1 in HIF2α Regulation
Burnett, D. (2010) · TSpace (University of Toronto)
Targeting Hsp90 Function to Treat Cancer: Much More to Be Learned
Whitesell, L., & Mclellan, C. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6401-2_13
“An example of an Hsp90 client that displays variant behavior in response to Hsp90 inhibition is HIF-1 , a key component of the heterodimeric complex that plays a central role in regulating tumor neovascularization (Isaacs et al., 2002; Kaur et al., 2004; Sanderson et al., 2006).”
BackgroundWoan, K. V. (2012) · University of Florida Digital Collections (University of Florida)
Rahman, T., & Wezen, X. C. (2018) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624011-00055
Heat Shock Protein 90 and the Proteasome
Neckers, L. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10058-5
Self-citationHIF-1α as a Potential Therapeutic Target for Tuberculosis Treatment
Jiang, Q., Gennaro, M. L., & Shi, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-56905-1_4
Modulation of Protein Stability: Targeting the VHL Pathway
Kim, W. Y., & Kaelin, W. G. (2009) · Springer eBooks · doi:10.1007/978-0-387-69147-3_4
Neckers, L., & Ivy, P. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_4
Self-citationThe Role of the Ubiquitin–Proteasome Pathway in the Regulation of the Cellular Hypoxia Response
Nakayama, K., & Ronai, Z. A. (2006) · Wiley eBooks · doi:10.1002/9783527620227.ch6
Zhao, Z., Yang, J., Chen, H., Li, S., Hou, X., Ma, C., & Liu, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2952795/v1
Thymoquinone reduces methotrexate-induced heart damage: a histopathological study in rats
Yıldırım, A. B., Kaymak, E., Ceylan, T., Akın, A. T., Kuloğlu, N., Sayan, M., Değer, N., ÖNAL, E., & Karabulut, D. (2023) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1314101
Systemic Therapy Options in VHL Disease
Jonasch, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-53858-2_10
Additional file 3 of HIF1α-dependent hypoxia response in myeloid cells requires IRE1α
Mawambo, G., Oubaha, M., Ichiyama, Y., Blot, G., Crespo‐Garcia, S., Dejda, A., Binet, F., Diaz-Marin, R., Sawchyn, C., Sergeev, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23557898
Additional file 2 of HIF1α-dependent hypoxia response in myeloid cells requires IRE1α
Mawambo, G., Oubaha, M., Ichiyama, Y., Blot, G., Crespo‐Garcia, S., Dejda, A., Binet, F., Diaz-Marin, R., Sawchyn, C., Sergeev, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23557895
Additional file 4 of HIF1α-dependent hypoxia response in myeloid cells requires IRE1α
Mawambo, G., Oubaha, M., Ichiyama, Y., Blot, G., Crespo‐Garcia, S., Dejda, A., Binet, F., Diaz-Marin, R., Sawchyn, C., Sergeev, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23557901
Hypoxia-Inducible Factors: Regulation and Therapeutic Potential
Lin, I., Chang, K., Cheng, F., Kanwar, R. K., Kamplikar, P., Kanwar, J. R., & Cheung, C. H. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-1016-7_11 · Cited by 1
SNX-2112 inhibits the ERBB3 high tumor population in Plexiform NeurofibromasPreprint
Khan, S. A., Aina, O., Veneklasen, X., Bruckert, B., Njoya, K., Alson, D., Sun, L., Zayed, H., & Sun, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.26.650740
Nomura, Y., Aragane, A., Feng, Z., & Nakamura, T. (2005) · Biomedical research on trace elements · doi:10.11299/brte.16.318
Hypoxic gene regulation and high-throughput genetic mapping
Baird, N. A. (2008) · Scholars' Bank (University of Oregon)
Mo, Y., Zhang, Y., Zhang, Y., Yuan, J., Mo, L., & Zhang, Q. (2021) · Figshare · doi:10.6084/m9.figshare.17037522
Mo, Y., Zhang, Y., Zhang, Y., Yuan, J., Mo, L., & Zhang, Q. (2021) · Figshare · doi:10.6084/m9.figshare.17037516
Mo, Y., Zhang, Y., Zhang, Y., Yuan, J., Mo, L., & Zhang, Q. (2021) · Figshare · doi:10.6084/m9.figshare.17037525
Additional file 1 of HIF1α-dependent hypoxia response in myeloid cells requires IRE1α
Mawambo, G., Oubaha, M., Ichiyama, Y., Blot, G., Crespo‐Garcia, S., Dejda, A., Binet, F., Diaz-Marin, R., Sawchyn, C., Sergeev, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23557892
Guerrab, A. E. (2011) · theses.fr (ABES) · doi:10.70675/0680d6aez5ddfz48efzabe9zf58f93e15842
Rouault-Pierre, K. (2010) · theses.fr (ABES) · doi:10.70675/d19021d9z37c5z4948zb727z5f042b13da9d · Cited by 1
Chaddad, H. (2019) · theses.fr (ABES) · doi:10.70675/e2786a5az288az46d4za2afz98cdafddfe5b · Cited by 2
Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82
Role of hypoxia and metabolism in the maturation of hemodialysis arteriovenous fistulas
Sadaghianloo, N. (2018) · theses.fr (ABES) · doi:10.70675/dd46cd88z0b28z473fz9684zb469ec41bcf3
Clow, T. M., & Craig, P. M. (2026) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2026.112017 · Cited by 2
Diaz-Herreros, A. N., Reyes‐Maldonado, E., Rosales-Cruz, É., Gómez‐Chávez, F., Valdez-Guerrero, A. S., Rodríguez‐Cortés, O., Cancino‐Díaz, J. C., & Cancino-Diaz, M. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104640
Viperino, A., Hammerich, L., Biersack, B., Pradhan, S., Andronache, I., Groth, I., Edel, N., Höpfner, M., & Nitzsche, B. (2026) · Cancers · doi:10.3390/cancers18162640
Zhang, F., Wang, J., Xu, Y., Ma, M., Wei, S., & Liu, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1845179
“In addition, hypoxic tumors often experience proteotoxic stress and may be more dependent on molecular chaperones such as HSP90 for survival, which may explain their sensitivity to 17-AAG (Whitesell and Lindquist, 2005; Isaacs et al., 2002).”
MORC2 controls HIF-1α stability via an HDAC4-dependent mechanism to regulate erythropoiesis
Tang, Y., Zhang, B., Xue, T., Liu, Y., Li, Y., Gu, Y., Hao, J., & Lu, L. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2537114123
D’Aprile, I., Petrillo, G., Saleri, S., Marizzoni, M., Zonca, V., Mazzelli, M., Riva, M. A., & Cattaneo, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111949
Hypoxia–ROS–HSP Triad Axis in Cancer: Mechanisms, Crosstalk, and Therapeutic Implications
Singh, M. K., Yun, H. R., Ranbhise, J. S., Han, S., Yeo, S. G., Quan, F., Kim, B., Kim, S. S., & Kang, I. (2026) · Cells · doi:10.3390/cells15191802
BindingDB Entry 50040848: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
BindingDB (2013) · UC San Diego · doi:10.7270/q26d5v4n
Thérapie génique de l'angiogenèse tumorale ciblée par des cellules endothéliales immatures
Collet, G. (2012) · theses.fr (ABES) · doi:10.70675/7e00daa0z60f1z4874za3c4zce11f3b40617
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.